BidaskClub cut shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a report published on Saturday morning.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research raised Inogen from a hold rating to a buy rating and set a $290.00 price target on the stock in a research note on Thursday, September 27th. Piper Jaffray Companies lifted their price target on Inogen from $245.00 to $290.00 and gave the stock an overweight rating in a research note on Wednesday, September 12th. Needham & Company LLC cut Inogen from a strong-buy rating to a buy rating and boosted their target price for the company from $254.00 to $296.00 in a research note on Monday, September 10th. Finally, Stifel Nicolaus set a $258.00 target price on Inogen and gave the company a buy rating in a research note on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $247.33.

Inogen stock traded down $3.85 during trading hours on Friday, reaching $187.12. The company had a trading volume of 396,658 shares, compared to its average volume of 533,445. The stock has a market capitalization of $4.00 billion, a P/E ratio of 105.72, a price-to-earnings-growth ratio of 3.70 and a beta of 1.25. Inogen has a 12-month low of $94.46 and a 12-month high of $287.79.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, August 7th. The medical technology company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.21. The business had revenue of $97.24 million for the quarter, compared to analysts’ expectations of $81.61 million. Inogen had a return on equity of 16.51% and a net margin of 10.39%. As a group, sell-side analysts forecast that Inogen will post 2.07 earnings per share for the current year.

In other news, EVP Brenton Taylor sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $197.80, for a total transaction of $989,000.00. Following the transaction, the executive vice president now directly owns 41,576 shares of the company’s stock, valued at $8,223,732.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $282.57, for a total value of $2,966,985.00. Following the transaction, the director now directly owns 8,797 shares in the company, valued at $2,485,768.29. The disclosure for this sale can be found here. Insiders have sold 95,141 shares of company stock worth $21,660,725 over the last three months. Insiders own 5.29% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zacks Investment Management boosted its position in shares of Inogen by 1.6% during the second quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock valued at $3,174,000 after purchasing an additional 261 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in shares of Inogen by 0.4% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 72,381 shares of the medical technology company’s stock valued at $13,487,000 after purchasing an additional 291 shares in the last quarter. Sei Investments Co. boosted its holdings in Inogen by 10.5% in the first quarter. Sei Investments Co. now owns 3,073 shares of the medical technology company’s stock worth $377,000 after acquiring an additional 293 shares in the last quarter. Xact Kapitalforvaltning AB boosted its holdings in Inogen by 12.2% in the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock worth $515,000 after acquiring an additional 300 shares in the last quarter. Finally, Piedmont Investment Advisors LLC boosted its holdings in Inogen by 9.8% in the second quarter. Piedmont Investment Advisors LLC now owns 4,059 shares of the medical technology company’s stock worth $756,000 after acquiring an additional 361 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.